Literature DB >> 30108185

Inner Workings: Safer opioids may be on the horizon, but mitigating addiction is a long shot.

Jyoti Madhusoodanan.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30108185      PMCID： PMC6099854          DOI： 10.1073/pnas.1812313115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  8 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 2.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

3.  Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative.

Authors:  Francis S Collins; Walter J Koroshetz; Nora D Volkow
Journal:  JAMA       Date:  2018-07-10       Impact factor: 56.272

4.  A nontoxic pain killer designed by modeling of pathological receptor conformations.

Authors:  V Spahn; G Del Vecchio; D Labuz; A Rodriguez-Gaztelumendi; N Massaly; J Temp; V Durmaz; P Sabri; M Reidelbach; H Machelska; M Weber; C Stein
Journal:  Science       Date:  2017-03-03       Impact factor: 47.728

5.  N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.

Authors:  Ajay S Yekkirala; Mary M Lunzer; Christopher R McCurdy; Michael D Powers; Alexander E Kalyuzhny; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-08       Impact factor: 11.205

6.  Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia.

Authors:  Gregory Corder; Vivianne L Tawfik; Dong Wang; Elizabeth I Sypek; Sarah A Low; Jasmine R Dickinson; Chaudy Sotoudeh; J David Clark; Ben A Barres; Christopher J Bohlen; Grégory Scherrer
Journal:  Nat Med       Date:  2017-01-16       Impact factor: 53.440

7.  A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.

Authors:  Neil Singla; Harold S Minkowitz; David G Soergel; David A Burt; Ruth Ann Subach; Monica Y Salamea; Michael J Fossler; Franck Skobieranda
Journal:  J Pain Res       Date:  2017-10-06       Impact factor: 3.133

8.  Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits.

Authors:  Dong Wang; Vivianne L Tawfik; Gregory Corder; Sarah A Low; Amaury François; Allan I Basbaum; Grégory Scherrer
Journal:  Neuron       Date:  2018-03-22       Impact factor: 17.173
  8 in total
  1 in total

1.  In Vitro Effects of Ligand Bias on Primate Mu Opioid Receptor Downstream Signaling.

Authors:  Xiao Zhang; Shaurita D Hutchins; Bruce E Blough; Eric J Vallender
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.